NCT04258462View on ClinicalTrials.gov

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Benign Kidney NeoplasmKidney NeoplasmRenal Cell Cancer
Interventions
DRUG

Hyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Hyperpolarized 13C,15N2-urea

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Zhen Wang, MD

OTHER